StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for COSM yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $0.31 | $0.30 | -1.57% | 0.5M |
| 05-18 | $0.30 | $0.29 | -2.10% | 1.1M |
| 05-19 | $0.30 | $0.28 | -5.83% | 0.4M |
| 05-20 | $0.29 | $0.28 | -1.97% | 0.6M |
| 05-21 | $0.27 | $0.26 | -7.13% | 1.5M |
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $17.93M | $65.27M | $45.57M | $28.46M |
Operating Income | $-2.18M | $-16.70M | $-5.30M | $-3.48M |
Net Income | $-2.81M | $-19.14M | $-9.00M | $-3.65M |
EPS (Diluted) | $-0.06 | $-0.63 | $-0.32 | $-0.13 |
Total Assets | $62.37M | $65.48M | $69.49M | $61.84M |
Total Liabilities | $42.54M | $47.05M | $46.36M | $35.60M |
Cash & Equivalents | $514.70K | $715.67K | $889.44K | $655.50K |
Free Cash Flow OCF − CapEx | $-1.08M | $-8.50M | $-3.90M | $-1.43M |
Shares Outstanding | 41.07M | 23.60M | 31.87M | 29.72M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.